Biomea Fusion, Inc.
$2.05
▲
3.36%
2026-04-21 05:43:00
biomeafusion.com
NMS: BMEA
Explore Biomea Fusion, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$159.78 M
Current Price
$2.05
52W High / Low
$3.08 / $0.87
Stock P/E
—
Book Value
$0.41
Dividend Yield
—
ROCE
-171.28%
ROE
-1.52%
Face Value
—
EPS
$-1.18
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
41
Beta
-0.27
Debt / Equity
5.38
Current Ratio
5.23
Quick Ratio
5.23
Forward P/E
-1.76
Price / Sales
—
Enterprise Value
$80.98 M
EV / EBITDA
-1.01
EV / Revenue
—
Rating
Buy
Target Price
$7.17
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Enanta Pharmaceuticals, Inc. | $13.78 | — | $409.17 M | — | -36.76% | -60.01% | $17.15 / $4.83 | $4.36 |
| 2. | Alto Neuroscience, Inc. | $27.33 | — | $885.53 M | — | -38.28% | -41.8% | $28.11 / $2.09 | $4.74 |
| 3. | Celularity Inc. | $1.24 | — | $35.47 M | — | -48.8% | -232.51% | $4.35 / $1.01 | $-0.71 |
| 4. | Tempest Therapeutics, Inc. | $1.94 | — | $27.83 M | — | -195.16% | -2.04% | $12.23 / $1.5 | $1.35 |
| 5. | Amicus Therapeutics, Inc. | $14.46 | — | $4.54 B | — | 4.84% | -11.58% | $14.48 / $5.51 | $0.88 |
| 6. | Puma Biotechnology, Inc. | $7.37 | 12.05 | $374.96 M | — | 27.62% | 27.97% | $7.9 / $2.75 | $2.59 |
| 7. | Citius Pharmaceuticals, Inc. | $0.87 | — | $19.56 M | — | -44.79% | -47.85% | $2.48 / $0.63 | $3.57 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -11.72 M | -18.6 M | -21.28 M | -29.71 M | -30.07 M | — |
| Net Profit | 4.61 M | -16.41 M | -20.74 M | -29.26 M | -29.3 M | — |
| EPS in Rs | 0.06 | -0.23 | -0.29 | -0.4 | -0.41 | -0.91 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -81.31 M | -144.07 M | -126.14 M | -83.63 M |
| Net Profit | -61.8 M | -138.43 M | -117.25 M | -81.83 M |
| EPS in Rs | -0.85 | -1.91 | -1.62 | -1.13 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 58.57 M | 79.94 M | 199.93 M | 129.31 M |
| Total Liabilities | 29.02 M | 28.36 M | 30.69 M | 20.77 M |
| Equity | 29.55 M | 51.57 M | 169.24 M | 108.54 M |
| Current Assets | 58.05 M | 68.33 M | 179.18 M | 117.82 M |
| Current Liabilities | 11.1 M | 21.67 M | 22.86 M | 19.1 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -70.37 M | -119.89 M | -96.59 M | -62.42 M |
| Investing CF | 0 M | -0.36 M | -2.22 M | 27.34 M |
| Financing CF | 67.9 M | 1.67 M | 163.8 M | 1.24 M |
| Free CF | -70.37 M | -120.26 M | -99.96 M | -63.45 M |
| Capex | — | -0.36 M | -3.37 M | -1.03 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -18.06% | -43.29% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.